

# Formulary quarterly impact report

State of New Mexico RMD

Formulary type: Standard with ACSF

Claims Period: March 2023 - June 2023



This report contains confidential and proprietary information of CVS Health and cannot be reproduced, distributed or reprinted without permission from CVS Health. Every effort is made by CVS Caremark and its advisors to maintain the highest level of accuracy in its projections; however, because of the variability of a number of factors, which are not under the control of CVS Caremark, we cannot guarantee the estimated results shown.

Tier values of "X" indicate the drug is not part of CVS Caremark's standard formulary. Drug may be subject to PA/medical exceptions process or no drug coverage.

©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary

# Formulary quarterly impact report

## Current utilization summary

Distinct Utilizers	Rxs	Days	Gross	Net
31,969	235,514	7,461,521	\$34,180,624	\$31,516,676

## Estimated impact of formulary update

Change category	Member impact	Distinct utilizers impacted*	Percent (%) total utilizing members impacted	Impacted Rxs	Percent (%) total Rxs impacted
Exclusion	Positive	0	0.00%	0	0.00%
Exclusion	Negative	1	0.00%	1	0.00%
<b>Exclusion</b>	<b>Total</b>	<b>1</b>	<b>0.00%</b>	<b>1</b>	<b>0.00%</b>
Tier change	Positive	0	0.00%	0	0.00%
Tier change	Negative	159	0.50%	412	0.17%
<b>Tier change</b>	<b>Total</b>	<b>159</b>	<b>0.50%</b>	<b>412</b>	<b>0.17%</b>
<b>Total</b>		<b>160</b>	<b>0.50%</b>	<b>413</b>	<b>0.18%</b>

\*The sum of distinct utilizers is greater than the Total Impacted Distinct Utilizers due to overlap among positively impacted and negatively impacted products.

Also see disclaimer notes on cover page.  
©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary



# Formulary quarterly impact report - drug detail

## Formulary impact - drug detail

Drug name	Therapeutic class	Change category	Member impact	Current tier	New tier	Utilizers	Rxs	Current gross cost	Current member cost	Current net cost
VYVANSE	AMPHETAMINES	Tier Change	Negative	2	3	159	412	\$153,340	\$0	\$153,340
ZIEXTENZO	HEMATOPOIETIC GROWTH FACTORS	Exclusion	Negative	2	X	1	1	\$3,945	\$1,184	\$2,762